SCHEMBL25330960

SCHEMBL25330960

O=C(O)NC1Cc2ccccc2N(C(=O)C2CCCCC2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
BRD4 O60885 1/20 0.49
TSHR P16473 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
IDH1 O75874 1/20 0.45
MTNR1A P48039 2/20 0.44
MTNR1B P49286 2/20 0.44
MMP1 P03956 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
ADAM17 P78536 1/20 0.43
BCHE P06276 1/20 0.42
HTR2A P28223 1/20 0.42
LMNA P02545 3/20 0.42
HTT P42858 1/20 0.42
KEAP1 Q14145 1/20 0.41
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25330854 0.86 POLB (0.51) POLBBRD4TSHRSMN1; SMN2RAB9A
SCHEMBL30576483 0.86 POLB (0.51) POLBBRD4TSHRSMN1; SMN2RAB9A
SCHEMBL27057854 0.84 EPHX2 (0.51) POLBBRD4TSHRSMN1; SMN2RAB9A
SCHEMBL2981090 0.79 HPGD (0.52) SMN1; SMN2RAB9ANPC1MTNR1AMTNR1B
SCHEMBL25330360 0.77 MTNR1A (0.52) TSHRSMN1; SMN2RAB9ANPC1MTNR1A
SCHEMBL430403 0.74 MTNR1A (0.53) RAB9ANPC1MTNR1AMTNR1BLMNA
SCHEMBL4799619 0.74 MTNR1A (0.53) RAB9ANPC1MTNR1AMTNR1BLMNA
SCHEMBL29073309 0.74 POLB (0.54) POLBBRD4TSHRSMN1; SMN2RAB9A
SCHEMBL2986627 0.74 POLB (0.41) POLBBRD4TSHRIDH1MMP1
SCHEMBL14156261 0.73 POLB (0.86) POLBTSHRSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
EP-4222143-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER Katholieke Universiteit Leuven (BE) 2023-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER YAP1, TEAD2, TEAD1 POLB 2176/4885BRD4 104/4885TSHR 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.